1. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan.
- Author
-
Tu, Wen-Jun, Cao, Jianlei, Yu, Lei, Hu, Xiaorong, and Liu, Qiang
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *CYTOKINE release syndrome , *THERAPEUTIC use of monoclonal antibodies , *VIRAL pneumonia , *INTERLEUKINS , *CAUSES of death , *C-reactive protein , *MULTIPLE organ failure , *RETROSPECTIVE studies , *SEX distribution , *CRITICAL care medicine , *EPIDEMICS , *MENTAL health surveys , *RESEARCH funding , *COMORBIDITY , *FIBRIN fibrinogen degradation products - Abstract
A previous study suggested that the condition of 11 (11%) patients worsened in a short period of time and they died of multiple organ failure [[2]], while Wang et al. [[3]] reported that 4.3% of COVID-19 cases were fatal. A national study of 1099 patients with COVID-19 found that 55 patients (5%) were admitted to an intensive care unit and 15 (1.36%) succumbed to the infection [[4]]. All data are medians and interquartile ranges (IQR), with dot plots representing all values In summary, COVID-19 mortality is more common in older male patients with comorbidities and is mainly caused by multiple organ dysfunction syndrome. Tocilizumab (a monoclonal antibody targeting the interleukin-6 receptor) had been used to treat cytokine storm syndrome [[10]], and a clinical trial to assess its use in COVID-19 patients has been registered. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF